Cargando…

Prophylaxis use of clotting factor replacement products in people with non‐severe haemophilia: A review of the literature

INTRODUCTION: People with non‐severe haemophilia appear to be under‐treated in many countries, and this may lead to joint damage and worsen quality of life. AIM: To review literature for clotting factor replacement prophylaxis in people with non‐severe haemophilia A and B (HA/HB) in relation to long...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iorio, Alfonso, Königs, Christoph, Reding, Mark T., Rotellini, Dawn, Skinner, Mark W, Mancuso, Maria Elisa, Berntorp, Erik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091955/ https://www.ncbi.nlm.nih.gov/pubmed/36224704 http://dx.doi.org/10.1111/hae.14676

Ejemplares similares

Target joint resolution in patients with haemophilia A receiving long‐term prophylaxis with BAY 94‐9027
por: Reding, Mark T., et al.
Publicado: (2020)

Achieving the unimaginable: Health equity in haemophilia
por: Skinner, Mark W., et al.
Publicado: (2019)

The Role of Physiotherapy in the New Treatment Landscape for Haemophilia
por: Lobet, Sébastien, et al.
Publicado: (2021)

Haemophilia and joint disease: pathophysiology, evaluation, and management
por: Knobe, Karin, et al.
Publicado: (2011)

Area under the curve: Comparing the value of factor VIII replacement therapies in haemophilia A
por: Persson, Sofie, et al.
Publicado: (2022)

Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study
por: Reding, Mark T., et al.
Publicado: (2023)

Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review
por: Yu, Jacky K., et al.
Publicado: (2019)

Sports participation and physical activity in adult Dutch and Swedish patients with severe haemophilia: A comparison between intermediate‐ and high‐dose prophylaxis
por: Versloot, Olav, et al.
Publicado: (2019)

Sexual issues in people with haemophilia: Awareness and strategies for overcoming communication barriers
por: Blamey, Greig, et al.
Publicado: (2021)

Safety of intramuscular COVID‐19 vaccination in patients with haemophilia
por: Tiede, Andreas, et al.
Publicado: (2022)

Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study
por: Reding, Mark T., et al.
Publicado: (2021)

Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis
por: Mancuso, Maria Elisa, et al.
Publicado: (2021)

Recombinant factor VIII Fc for the treatment of haemophilia A
por: Hermans, Cedric, et al.
Publicado: (2021)

High adherence to prophylaxis regimens in haemophilia B patients receiving rIX‐FP: Evidence from clinical trials and real‐world practice
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

Haemophilia A: Pharmacoeconomic Review of Prophylaxis Treatment versus On-Demand
por: Unim, Brigid, et al.
Publicado: (2015)

Medication Adherence for Haemophilia Patients: Outcome of Prophylaxis Treatment Intervention
por: Mokhtar, Fadzlin Mohd, et al.
Publicado: (2021)

S303: A PHASE 3 STUDY (ATLAS-PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXIS
por: Kenet, Gili, et al.
Publicado: (2023)

Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A
por: Schmitt, Christophe, et al.
Publicado: (2022)

Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company
por: Hay, Charles R. M., et al.
Publicado: (2020)

A new paradigm for personalized prophylaxis for patients with severe haemophilia A
por: Delavenne, Xavier, et al.
Publicado: (2020)

Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B
por: Mahlangu, Johnny, et al.
Publicado: (2021)

Personalised Prophylaxis in a Child with Haemophilia A and Type 1 Diabetes
por: Cruz, Maria Sol, et al.
Publicado: (2021)

Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A
por: Shah, Anita, et al.
Publicado: (2019)

Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A
por: Solms, Alexander, et al.
Publicado: (2020)

Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study
por: Kenet, Gili, et al.
Publicado: (2021)

A new measure to assess pain in people with haemophilia: The Multidimensional Haemophilia Pain Questionnaire (MHPQ)
por: Paredes, Ana Cristina, et al.
Publicado: (2018)

Shared topics on the experience of people with haemophilia living in the UK and the USA and the influence of individual and contextual variables: Results from the HERO qualitative study
por: Palareti, Laura, et al.
Publicado: (2015)

Total Hip Replacement in Severe Haemophilia A: Challenges and Feasibility
por: Bhattacharjee, Sujoy K, et al.
Publicado: (2022)

The Patient Reported Outcomes, Burdens and Experiences (PROBE) Project: development and evaluation of a questionnaire assessing patient reported outcomes in people with haemophilia
por: Skinner, MW., et al.
Publicado: (2018)

Hæmophilia
Publicado: (1905)

Hæmophilia
por: Ruggles, S. D.
Publicado: (1902)

Hæmophilia
por: Porter, Charles A.
Publicado: (1900)

Adherence to Prophylaxis in Adolescents and Young Adults with Severe Haemophilia: A Quantitative Study with Patients
por: van Os, Sandra B., et al.
Publicado: (2017)

A Comparison of the Incidence Rate for Joint Bleeding and FVIII Consumption between On-Demand versus Prophylaxis Factor VIII Replacement Therapy and the Direct Cost of Prophylaxis Treatment in Severe Haemophilia A Patients
por: Jamal, Munirah, et al.
Publicado: (2023)

International consensus recommendations on the management of people with haemophilia B
por: Hart, Daniel P., et al.
Publicado: (2022)

Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study
por: Kiialainen, Anna, et al.
Publicado: (2022)

Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors
por: Antunes, S V, et al.
Publicado: (2014)

BAY 81‐8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study
por: Santoro, Cristina, et al.
Publicado: (2020)

Adherence to prophylaxis in adolescents and young adults with severe haemophilia: a qualitative study with healthcare professionals
por: van Os, S., et al.
Publicado: (2020)

Adherence to prophylaxis in adolescents and young adults with severe haemophilia A, a qualitative study with patients
por: van Os, S., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4ihb7edj5hlqnfqq9b7pce4fc9